Xenoestrogens down-regulate aryl-hydrocarbon receptor nuclear translocator 2 mRNA expression in human breast cancer cells via an estrogen receptor alpha-dependent mechanism

Toxicology Letters

Volumn 206, Issue 2, 2011, Pages 152-157

  Qin, Xian Yang ^a,b   Zaha, Hiroko ^a   Nagano, Reiko ^a   Yoshinaga, Jun ^b   Yonemoto, Junzo ^a   Sone, Hideko ^a  

^a NATIONAL INSTITUTE FOR ENVIRONMENTAL STUDIES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

ARNT2; E CALUX; Endocrine disruption; Tumorigenesis; Xenoestrogen

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR 2; CARRIER PROTEINS AND BINDING PROTEINS; CHLORPHENOTANE; ENDOCRINE DISRUPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESSENGER RNA; PHTHALIC ACID BENZYL BUTYL ESTER; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; XENOESTROGEN;

ARTICLE; CANCER CELL CULTURE; CELL LINE; CELL STRAIN BG1LUC4E2; CELL STRAIN LNCAP; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; ESTROGEN ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; TOXICOKINETICS;

ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BREAST NEOPLASMS; CELL LINE, TUMOR; DDT; DOWN-REGULATION; ENDOCRINE DISRUPTORS; ESTROGEN RECEPTOR ALPHA; ESTROGENS, NON-STEROIDAL; FEMALE; GENES, REPORTER; HUMANS; NEOPLASM PROTEINS; OSMOLAR CONCENTRATION; OVARIAN NEOPLASMS; PHENOLS; PHTHALIC ACIDS; PIPERIDINES; PYRAZOLES; RESPONSE ELEMENTS; RNA, MESSENGER; XENOBIOTICS;

EID: 80052085353     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.07.007     Document Type: Article

References (33)

1. Alexander B., Browse D.J., Reading S.J., Benjamin I.S. A simple and accurate mathematical method for calculation of the EC50. J. Pharmacol. Toxicol. Methods 1999, 41:55-58.
2. Brandenberger A.W., Tee M.K., Jaffe R.B. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. J. Clin. Endocrinol. Metab. 1998, 83:1025-1028.
3. Buteau-Lozano H., Velasco G., Cristofari M., Balaguer P., Perrot-Applanat M. Xenoestrogens modulate vascular endothelial growth factor secretion in breast cancer cells through an estrogen receptor-dependent mechanism. J. Endocrinol. 2008, 196:399-412.
4. Dougherty E.J., Pollenz R.S. Analysis of Ah receptor-ARNT and Ah receptor-ARNT2 complexes in vitro and in cell culture. Toxicol. Sci. 2008, 103:191-206.
5. Ghisari M., Bonefeld-Jorgensen E.C. Effects of plasticizers and their mixtures on estrogen receptor and thyroid hormone functions. Toxicol. Lett. 2009, 189:67-77.
6. Ghosh M.G., Thompson D.A., Weigel R.J. PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. Cancer Res. 2000, 60:6367-6375.
7. Hankinson O. Why does ARNT2 behave differently from ARNT?. Toxicol. Sci. 2008, 103:1-3.
8. Harrington W.R., Sheng S., Barnett D.H., Petz L.N., Katzenellenbogen J.A., Katzenellenbogen B.S. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol. Cell. Endocrinol. 2003, 206:13-22.
9. Hatch E.E., Troisi R., Wise L.A., Titus-Ernstoff L., Hyer M., Palmer J.R., Strohsnitter W.C., Robboy S.J., Anderson D., Kaufman R., Adam E., Hoover R.N. Preterm birth, fetal growth, and age at menarche among women exposed prenatally to diethylstilbestrol (DES). Reprod. Toxicol. 2010.
10. Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J., Tujague M., Strom A., Treuter E., Warner M., Gustafsson J.A. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 2007, 87:905-931.
11. Hevir N., Trost N., Debeljak N., Rizner T.L. Expression of estrogen and progesterone receptors and estrogen metabolizing enzymes in different breast cancer cell lines. Chem. Biol. Interact. 2011, 191:206-216.
12. Hill A.J., Heiden T.C., Heideman W., Peterson R.E. Potential roles of Arnt2 in zebrafish larval development. Zebrafish 2009, 6:79-91.
13. Hirose K., Morita M., Ema M., Mimura J., Hamada H., Fujii H., Saijo Y., Gotoh O., Sogawa K., Fujii-Kuriyama Y. cDNA cloning and tissue-specific expression of a novel basic helix-loop-helix/PAS factor (Arnt2) with close sequence similarity to the aryl hydrocarbon receptor nuclear translocator (Arnt). Mol. Cell. Biol. 1996, 16:1706-1713.
14. Hosoya T., Oda Y., Takahashi S., Morita M., Kawauchi S., Ema M., Yamamoto M., Fujii-Kuriyama Y. Defective development of secretory neurones in the hypothalamus of Arnt2-knockout mice. Genes Cells 2001, 6:361-374.
15. Hsu H.J., Wang W.D., Hu C.H. Ectopic expression of negative ARNT2 factor disrupts fish development. Biochem. Biophys. Res. Commun. 2001, 282:487-492.
16. Kretzschmar G., Papke A., Zierau O., Moller F.J., Medjakovic S., Jungbauer A., et al. Estradiol regulates aryl hydrocarbon receptor expression in the rat uterus. Mol. Cell. Endocrinol. 2010, 321(2):253-257.
17. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., Gustafsson J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138:863-870.
18. Ma L. Endocrine disruptors in female reproductive tract development and carcinogenesis. Trends Endocrinol. Metab. 2009, 20:357-363.
19. Maltepe E., Keith B., Arsham A.M., Brorson J.R., Simon M.C. The role of ARNT2 in tumor angiogenesis and the neural response to hypoxia. Biochem. Biophys. Res. Commun. 2000, 273:231-238.
20. Martinez V., Kennedy S., Doolan P., Gammell P., Joyce H., Kenny E., Prakash Mehta J., Ryan E., O'Connor R., Crown J., Clynes M., O'Driscoll L. Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue. Breast Cancer Res. Treat. 2008, 110:521-530.
21. Mitsushima D., Funabashi T., Kimura F. Estrogen increases messenger RNA and immunoreactivity of aryl-hydrocarbon receptor nuclear translocator 2 in the rat mediobasal hypothalamus. Biochem. Biophys. Res. Commun. 2003, 307:248-253.
22. Rogers J.M., Denison M.S. Recombinant cell bioassays for endocrine disruptors: development of a stably transfected human ovarian cell line for the detection of estrogenic and anti-estrogenic chemicals. In Vitro Mol. Toxicol. 2000, 13:67-82.
23. Rogers J.M., Denison M.S. Analysis of the antiestrogenic activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in human ovarian carcinoma BG-1 cells. Mol. Pharmacol. 2002, 61:1393-1403.
24. Safe S. Endocrine disruptors and human health: is there a problem. Toxicology 2004, 205:3-10.
25. Scherbakov A.M., Lobanova Y.S., Shatskaya V.A., Krasil'nikov M.A. The breast cancer cells response to chronic hypoxia involves the opposite regulation of NF-kB and estrogen receptor signaling. Steroids 2009, 74:535-542.
26. Schlezinger J.J., Liu D., Farago M., Seldin D.C., Belguise K., Sonenshein G.E., Sherr D.H. A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. Biol. Chem. 2006, 387:1175-1187.
27. Sekine H., Mimura J., Yamamoto M., Fujii-Kuriyama Y. Unique and overlapping transcriptional roles of arylhydrocarbon receptor nuclear translocator (Arnt) and Arnt2 in xenobiotic and hypoxic responses. J. Biol. Chem. 2006, 281:37507-37516.
28. Sharpe R.M., Irvine D.S. How strong is the evidence of a link between environmental chemicals and adverse effects on human reproductive health?. BMJ 2004, 328:447-451.
29. Sikka S.C., Wang R. Endocrine disruptors and estrogenic effects on male reproductive axis. Asian J. Androl. 2008, 10:134-145.
30. Swedenborg E., Pongratz I. AhR and ARNT modulate ER signaling. Toxicology 2010, 268:132-138.
31. Watanabe M., Yoshida R., Ueoka K., Aoki K., Sasagawa I., Hasegawa T., Sueoka K., Kamatani N., Yoshimura Y., Ogata T. Haplotype analysis of the estrogen receptor 1 gene in male genital and reproductive abnormalities. Hum. Reprod. 2007, 22:1279-1284.
32. Welshons W.V., Thayer K.A., Judy B.M., Taylor J.A., Curran E.M., vom Saal F.S. Large effects from small exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity. Environ. Health Perspect. 2003, 111:994-1006.
33. Ziello J.E., Jovin I.S., Huang Y. Hypoxia-inducible factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J. Biol. Med. 2007, 80:51-60.